CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.